Q-omics provides the consensus-scored ZNF44 profile across patient tissues and cancer cell-line models. ZNF44 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF44 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ZNF44 RNA expression shows 21,351 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where ZNF44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF44 survival associations across molecular data types. ZNF44 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF44 RNA expression–survival associations across cancer types. High ZNF44 expression shows unfavorable associations in LGG and ACC, but favorable associations in BLCA, HNSC, BRCA and GBM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF44 RNA expression.
This table summarizes ZNF44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF44 shows lower tumor expression in KIRC, THCA, KIRP, LUAD, KICH and LUSC. The KIRC box plot shows higher ZNF44 RNA expression in normal versus tumor tissue (log2 FC = −1.521, t-test p < 0.001).
This table shows molecular features associated with ZNF44 in patient tissues and cancer cell lines. In patient samples, ZNF44 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
